Combining a CB1 receptor blocker with a NOP receptor activator unexpectedly worsened intestinal inflammation in a mouse colitis model, revealing a complex interaction between the endocannabinoid and nociceptin systems.
IBD researchers, pharmacologists developing endocannabinoid-targeting drugs, and scientists studying receptor system interactions.
Combination treatment worsened colitis beyond either agent alone
What the researchers found
Mice with DSS-induced colitis treated with both AM6545 and SCH221510 showed significantly worse macroscopic disease scores and altered signaling compared to SCH221510 alone.
Why it matters
Both the endocannabinoid system and NOP receptors are being explored as IBD targets. This study reveals that their interaction can worsen rather than improve outcomes.
The numbers in context
Significant increase in macroscopic colitis score with AM6545+SCH221510 vs SCH221510 alone. Lower ERK1/2 levels. Higher p-AKT and beta-arrestin in the combination group.
How the study worked
Mouse colitis model using 3% DSS, with selective ligands for CB1 (antagonist AM6545), CB2 (antagonist AM630), and NOP receptor (agonist SCH221510). Assessed macroscopic/microscopic scores, western blots, qPCR, and LC-MS.
What this study cannot tell us
Single mouse colitis model (DSS). Only acute colitis studied. Mechanism not fully elucidated.
How to read the evidence
Well-designed animal study with multiple molecular endpoints, but findings need validation across other IBD models.
When this study was published
Published in 2025.
The bigger picture
Drug development for IBD increasingly targets the endocannabinoid system. This cautionary finding shows receptor interactions must be carefully studied before combination therapies.
Questions still open
- Would CB2 antagonism produce similar adverse interactions? Is this interaction relevant to humans with IBD?
Common questions
Can targeting the endocannabinoid system help with colitis?
What does this mean for drug development?
Read the original research
Combined CB1 antagonist AM6545 and NOP agonist SCH221510 worsen DSS-induced colitis in mice.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 34(12), 2153-2162
Citation
Fabisiak, Adam; Wołyniak, Maria R; Piscitelli, Fabiana; Verde, Roberta; Marzo, Vincenzo Di; Zielińska, Marta; Machelak, Weronika; Małecka-Wojciesko, Ewa. (2025). Combined CB1 antagonist AM6545 and NOP agonist SCH221510 worsen DSS-induced colitis in mice.. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 34(12), 2153-2162. https://doi.org/10.17219/acem/203426
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk